Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

NanJing Public Utilities Development frequently takes action to transform, will the battery-swapping Technology company Yugu reach the public market through a curve? | Quick reading of the announcement.

① NanJing Public Utilities Development plans to acquire YuGu Technology, whose main Business provides battery swapping services for delivery riders, having halted its IPO process six months ago; ② In recent years, while YuGu Technology's revenue has grown, its gross margin has continued to decline, and NanJing Public Utilities Development has fallen into a loss trap; ③ NanJing Public Utilities Development is frequently acquiring external Assets to accelerate its transformation towards New energy Fund, and recently acquired NanJing Energy Network.

cls.cnJan 10 10:44 ET

Repurchase amount does not meet the standard, jilin yatai group is ordered to make corrections | Speed reading announcement

①Upon the expiration of the repurchase period, jilin yatai repurchased amount is below the lower limit of the total repurchase amount, jilin Securities Regulatory Bureau requested correction. ②Jilin Securities Regulatory Bureau decided to take regulatory measures to order the company to make corrections, and record it in the integrity files of the securities and futures market.

cls.cnNov 8, 2024 10:46 ET

Companies with long-term net asset value per share below book value must disclose plans for valuation improvement. State-owned enterprises with net asset value per share below book value are expected to attract incremental funds.

On September 24, the China Securities Regulatory Commission publicly solicited opinions on the 'Guidelines for the Supervision of Listed Companies No. 10 - Market Cap Management (Consultation Draft)'. The guidelines require long-term companies trading below net asset value to disclose their valuation enhancement plans, including targets, deadlines, specific measures, and provide special explanations on the execution of the valuation enhancement plan during the annual performance briefing.

cls.cnSep 24, 2024 19:59 ET

The State Council meeting promotes a virtuous cycle in the venture capital industry, and the sector is expected to seize the opportunity.

On September 18th, the executive meeting of the State Council pointed out that venture capital is related to technological innovation, industrial upgrading, and high-quality development. It is necessary to quickly resolve the bottlenecks and difficulties in the various stages of fundraising, investment management, and withdrawal, support eligible technology-based enterprises to list both domestically and internationally, vigorously develop the equity transfer and mergers and acquisitions market, and promote a healthy cycle in the venture capital industry.

cls.cnSep 18, 2024 19:41 ET

On September 10, 11 companies, including Tiantan Biology and China Satcom, announced positive results.

1. Tiantan Biology: Chengdu Rongsheng related production site has passed the drug GMP compliance test Tiantan Biological announcement, Chengdu Rongsheng developed "Human Coagulation Factor Ⅷ" meets the relevant requirements of drug registration. At the same time, Chengdu Rongsheng related production sites have passed the drug GMP compliance inspection, and obtained the "Drug GMP on-the-spot Inspection result notice" issued by the Sichuan Provincial Drug Administration. two。 China Satcom: China Star 9B satellite will be delivered to the company after passing the in-orbit test. China Satcom announced that the China Star 9B satellite launched on September 9 will be delivered to the company's operation management after passing the in-orbit test.

證券之星Sep 10, 2021 05:58 ET